In 1995, a series of proposed reforms to reduce regulatory burden on pharmaceutical manufacturers were announced, including an expansion of allowable promotional material on approved uses of drugs that firms can distribute to health professionals, streamlining certain elements in the documentation of investigational drug studies, and a reduction in both environmental impact filings and pre-approval requirements in tablet manufacture.